Pharma Surge
Pharma Surge
Intelligence Layer
🇺🇸·Jun 2Media

Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks

Publisher

F
FierceBiotech

USA

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
FierceBiotech
Region
USA
Scope
Media
Published
June 2, 2026

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Source route

Continue on fiercebiotech.com

Leave the platform to read the original full article on the publisher site.

Source: FierceBiotech

Scope: Media

Open original article
Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks | Pharma Surge